
    
      BCD-017-3 is an double-blind randomized phase III clinical study to compare the incidence of
      CTCAE grade 3/4 neutropenia after a single administration of recombinant human pegylated
      filgrastim empegfilgrastim (Extimia®) at a dose of 6 or 7.5 mg versus daily administration of
      filgrastim at a dose of 5 μg/kg/day for neutropenia prophylaxis in breast cancer patients
      receiving myelosuppressive chemotherapy.

      The study also includes the following determination of pharmacokinetic parameters after
      repeated administration of the study drug.
    
  